WAM
HQL

Wolverine Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History

Wolverine Asset Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$607K Sell
37,335
-59,787
-62% -$999K 0.01% 893
2025
Q4 		$1.63M Sell
97,122
-118,399
-55% -$1.99M 0.01% 652
2025
Q3 		$3.34M Buy
215,521
+72,601
+51% +$994K 0.02% 443
2025
Q2 		$1.83M Buy
142,920
+17,382
+14% +$214K 0.02% 550
2025
Q1 		$1.59M Buy
125,538
+4,075
+3% +$55.2K 0.02% 574
2024
Q4 		$1.59M Buy
+121,463
New +$1.75M 0.02% 583
2024
Q2 		– Sell
-14,929
Closed -$203K – 1701
2024
Q1 		$203K Sell
14,929
-192,463
-93% -$2.66M ﹤0.01% 955
2023
Q4 		$2.79M Sell
207,392
-114,766
-36% -$1.41M 0.02% 462
2023
Q3 		$4.02M Buy
322,158
+86,671
+37% +$1.14M 0.05% 367
2023
Q2 		$3.19M Sell
235,487
-70,853
-23% -$978K 0.04% 393
2023
Q1 		$4.27M Buy
306,340
+35,802
+13% +$512K 0.05% 353
2022
Q4 		$3.84M Buy
270,538
+55,266
+26% +$801K 0.04% 403
2022
Q3 		$2.94M Buy
215,272
+62,091
+41% +$928K 0.03% 459
2022
Q2 		$2.18M Buy
153,181
+128,553
+522% +$1.94M 0.02% 531
2022
Q1 		$407K Buy
+24,628
New +$424K ﹤0.01% 1031
2020
Q3 		– Sell
-2,587
Closed -$46K – 1639
2020
Q2 		$46K Sell
2,587
-302,987
-99% -$5.19M ﹤0.01% 1245
2020
Q1 		$4.58M Sell
305,574
-31,975
-9% -$524K 0.07% 221
2019
Q4 		$5.88M Buy
337,549
+118,994
+54% +$1.95M 0.07% 222
2019
Q3 		$3.3M Buy
218,555
+44,027
+25% +$705K 0.04% 302
2019
Q2 		$2.94M Sell
174,528
-7,319
-4% -$121K 0.04% 350
2019
Q1 		$3.12M Buy
181,847
+43,774
+32% +$756K 0.04% 320
2018
Q4 		$2.09M Buy
+138,073
New +$2.43M 0.03% 537
2018
Q3 		– Sell
-60,362
Closed -$1.13M – 1551
2018
Q2 		$1.13M Buy
60,362
+4,872
+9% +$91.7K 0.01% 727
2018
Q1 		$1.07M Buy
+55,490
New +$1.11M 0.01% 741
2015
Q4 		– Sell
-17,723
Closed -$398K – 1794
2015
Q3 		$398K Buy
+17,723
New +$496K 0.01% 728
2014
Q4 		– Sell
-10,820
Closed -$239K – 2336
2014
Q3 		$239K Buy
+10,820
New +$235K 0.01% 976
2013
Q4 		– Sell
-25,122
Closed -$483K – 2780
2013
Q3 		$483K Buy
+25,122
New +$481K 0.01% 773

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wolverine Asset Management's HQL Position: Q1 2026 in Review

Wolverine Asset Management reduced its abrdn Life Sciences Investors (HQL) stake by 62% in Q1 2026, selling an estimated $999K and leaving 37,335 shares worth $607K. The position accounts for 0.01% of the portfolio, ranked #893.

Wolverine Asset Management first reported a position in HQL in Q3 2013 and has held it in 27 quarters since. The position peaked at $5.88M in Q4 2019. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Wolverine Asset Management held 37,335 shares of abrdn Life Sciences Investors worth $607K as of Q1 2026.
  • Wolverine Asset Management sold 59,787 abrdn Life Sciences Investors shares in Q1 2026, an estimated $999K.
  • abrdn Life Sciences Investors made up 0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #893 holding.
  • Wolverine Asset Management first reported a position in abrdn Life Sciences Investors in Q3 2013 and has held it in 27 quarters since.
  • Wolverine Asset Management's abrdn Life Sciences Investors position peaked at $5.88M in Q4 2019.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.